Purchasing a pipeline – perils, pitfalls, and priorities in asset acquisition

Checkpoint inhibitors. Genetic therapies. Biomarker therapies. To hear big pharma tell it, we are living in an age of medical wonders.

The problem? In some patients, they make a huge difference. In others, they don’t work at all.

From a bench-science standpoint, that’s fascinating. But if you’re a pharmaceutical executive thinking seriously about pipeline asset acquisition, translating large-molecule science into high-profit marketability is fraught with complexity.

In this White Paper, we will look at new and changing trends in pipeline acquisition, discuss difficulties inherent in the current marketplace, and offer worthwhile perspectives on pitfalls and opportunities based on our experience offering strategic guidance to pharmaceutical companies on a global scale.

Big pharma pipelines are not what they used to be

The majority of new drugs measure their success in increments.

Orphan drugs and tightly targeted MOAs offer the most exciting breakthroughs, but they offer them to smaller and smaller groups of patients. New cancer drugs are launched with great fanfare even when their pivotal studies suggest they offer a scant three months’ improvement over the competition. Small molecules are languishing. Biologics, once heralded as an arena of unbounded promise, are nearing the end of their patent lives, negotiating payments worth millions to keep biosimilars off the market.

Deallus Purchasing a Pipeline White Paper
DOWNLOAD WHITE PAPER

You may also be interested in…

How is COVID-19 impacting clinical trials?

As the impact of COVID-19 pandemic continues to expand globally, pharmaceutical and biotech players are beginning to feel the disruptive effects of the outbreak. New clinical trials will be significantly delayed as companies continue to face challenges arising from COVID-19, from potential patient quarantines, to site closures, travel limitations or interruptions to the supply chain for new investigational products.

  • Deallus Announce New Strategic Advisor

Jennifer Cummins joins Deallus as Strategic Advisor

Deallus is excited to announce that Jenny Cummins will be partnering with Deallus as a Strategic Advisor. Jenny’s experience in formulating strategic direction within and outside of pharmaceutical companies is something we are excited to add to our panel of strategic advisors. Our clients will benefit from her expertise in the healthcare sector as well as her impressive leadership, communication, and facilitation skills.

  • Deallus Announce New Senior Principal

Gloria Kwon Joins Deallus as Senior Principal

We are excited to announce that Gloria Kwon has joined our Deallus team as a Senior Principal based out of our Los Angeles office. Gloria comes to Deallus with significant experience in business strategy, product commercialization and operational excellence for pharmaceutical and biotechnology companies. Prior to joining Deallus, Gloria spent over 8 years at Navigant Consulting.

  • Peter Barschdorff joins Deallus as Vice President (U.S.)

Peter Barschdorff joins Deallus as Vice President (U.S.)

Deallus is pleased to announce that Peter Barschdorff is joining the organization as Vice President, leading its U.S. consulting business, with offices in Los Angeles and New York. Peter has held leadership positions in a number of management consulting organizations and has built innovative enterprise capabilities in commercial pharma.